Biogen compiles buyout target list as Aduhelm woe deepens: Stat

Biogen has found itself increasingly deeper in the quagmire that is the Alzheimer’s disease drug Aduhelm. Like any beleaguered company might do, the Big Biotech is said to be weighing several strategic options.